Compound
← Compound
Official website →
GSKGSK plc
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- GSK
- Moeda das demonstrações
- GBP
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
15.65×
P/B
Price divided by book value
4.27×
EV/EBITDA
Enterprise value divided by operating cash generation
8.25×
EV/Revenue
Enterprise value divided by revenue
2.72×
What the company earns
ROE
Return on shareholders’ equity
28.3%
ROA
Return on all assets
7.8%
Gross margin
What remains after product costs
73.3%
Operating margin
What remains after operating the business
24.1%
Net margin
How much of each revenue unit becomes profit
14.5%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
1.03
Total debt
Sum of borrowings
£18.13B
Cash
Cash available to cover it
£3.09B
Current ratio
Short-term assets divided by short-term liabilities
0.82
Free cash flow
Cash left after investing
£2.21B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.29
Revenue growth
Compared with the same period a year earlier
5.3%
Earnings growth
Compared with the same period a year earlier
-69.9%
Dividend yield
Trailing 12-month distributions divided by price
3.6%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(GBP)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 29.32B | 30.33B | 31.38B | 32.67B |
| Custo dos produtos | -9.55B | -8.57B | -9.05B | -9.02B |
| Lucro bruto | 19.77B | 21.76B | 22.33B | 23.65B |
| Pesquisa e desenvolvimento | -5.49B |
Follow GSK and get agent analysis of what is moving the stock.
Open Compound